Developing and diversifying respite structures
Consolidating rights and training for carers
Improving health monitoring for family carers
Quality labelling throughout the country for "single points of contact", the "Maisons pour l’Autonomie et l’Intégration des malades Alzheimer" (MAIA)
Establishing "coordinators" throughout the country
Reinforcing support at home, advocating services by trained staff
Improving support at home using new technologies
Preparing and implementing a system for giving the diagnosis and providing counselling
Experimenting new payment terms for health professionals
Creating an Alzheimer’s disease information card for each patient
Creating memory units in areas that are not covered
Creating "memory resource and research centres" in areas that are not covered
Reinforcing the very active memory units
Monitoring drug-related iatrogenic accidents
Improving correct use of drugs
Creating specific units for patients suffering from behavioural problems within EHPADs
Creating specialized units within health care rehabilitation and follow-up (SSR) departments for Alzheimer’s patients
Accommodation for young patients
Identifying a national reference centre for young Alzheimer’s patients
A specific career and skills development plan for Alzheimer’s disease
Creating a foundation for scientific cooperation to stimulate and coordinate scientific research
Developing clinical research of Alzheimer’s disease and improving evaluation of non-drug therapies
Doctoral and post-doctoral grants
New assistant surgeon and hospital teaching assistant positions
Research in human and social sciences
Support for research groups working on innovative approaches
Support for methodological research groups in human and social sciences
Creation of a body of research in automatic image processing
Studying large patient populations (cohorts) with long-term monitoring
Exploiting the genome sequencing of the microcebe
Training in clinical epidemiology
Developing links between public research and industry
Setting up epidemiological surveillance and follow up
Setting up a telephone helpline and a website for information and local advice
Holding regional conferences to support the implementation of the plan
Studying disease knowledge and attitudes
Creating a space for ethical thought about Alzheimer’s disease
Launching a discussion about the legal status of Alzheimer’s patients in institutions
Organising regular meetings focusing on the autonomy of people suffering from Alzheimer’s disease
Informing patients and their families about trials implemented in France
Making the fight against Alzheimer’s disease a priority for the European Union during the French presidency
Publicizing and promoting research across Europe
Holding a European conference in autumn 2008
Studying opinion and attitude about Alzheimer’s disease and the impact of the plan among patients and carers
To improve knowledge of iatrogenesis in Alzheimer’s patients and develop surveillance.
Developing partnerships with geriatrics centres or correspondents:
The Regional Drug safety Centres (Centres régionaux de Drug safety, CRPV, of which France has 31), due to their integration within university hospitals and their regionalisation, have already developed partnerships with geriatrics departments and correspondents in health centres or in independent practice with a high degree of contact with elderly patients. Certain CRPVs (such as Limoges and Caen) have also developed more specific gerontological approaches for collecting details of undesirable side-effects and researching medication in elderly people.
Training and informing geriatricians:
The CRPVs have an important role in the correct use of medication through three strongly developed activities:
1- collecting details of undesirable side-effects, accompanied by dialogue between the person making the report and the centre to evaluate the issue and return conclusions about the case.
2- requesting information about medication in order to respond to over 20,000 increasingly complex questions a year.
3- drug safety training as part of the curriculum for health professions and in continuing training. Currently the CRPV network provides over 2,700 hours of training.
These activities that are already in place could be targeted more at the specific aspect of training and information for geriatricians and health professionals providing care for elderly people and especially Alzheimer’s patients.
Undesirable side-effects from the National Drug safety Database - 2006
|90 and over||371||3,5%||189||1,9%||560||2,7%|
Surveying the prevalence of undesirable side-effects in Alzheimer’s patients
Carrying out a survey of prevalence with the method used in the 1998 hospital survey "Iatrogénie médicamenteuse : estimation de sa prévalence dans les hôpitaux publics français" (Drug-related iatrogenesis: estimation of its prevalence in French public hospitals). However, in order to obtain a representative sample of the population of Alzheimer’s patients, the survey should be carried out in both public and private institutions and should include residential centres for elderly dependent people (établissements d’hébergement pour personnes âgées dépendantes, EHPADs).